Purdue Pharma pleads guilty to criminal charges, admits role in opioid epidemic


Purdue Pharma, which produces on OxyContin, on Tuesday admitted its role in the growth of the United States' opioid epidemic, pleading guilty to a set of criminal charges as part of a settlement with the federal government, The Associated Press reports.
The guilty plea included admissions that the pharmaceutical giant impeded the Drug Enforcement Administration's efforts to combat the opioid crisis. The company admitted it failed to maintain an effective program (despite assuring the DEA otherwise) focused on preventing prescription drugs from making it onto the black market. It provided the agency with misleading information so it could boost manufacturing quotas, and paid doctors through a speakers program as incentive for them to write more painkiller prescriptions.
The company will pay the federal government $225 million in the settlement, which is just a fraction of the $8.3 billion it owes in penalties and forfeitures. Paying the smaller amount is dependent on Purdue executing settlements while moving through bankruptcy court with state and local governments, and other groups that are also suing the company.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Many of the other plaintiffs are unsatisfied with the settlement, AP notes, especially because members of the Sackler family who own Purdue are not facing criminal charges and, despite owing the U.S. government millions and giving up control of the company, will not see their overall wealth affected significantly. Several state attorneys general also oppose Purdue's plans for future settlements, which include transforming into a public benefit corporation that would use its proceeds to address the opioid crisis. Read more at The Associated Press.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
The Week Unwrapped: Why are we watching the ocean floor?
Podcast Plus, what can we learn from a football club on the brink? And which jobs will fall to AI first?
-
Quiz of The Week: 2 – 8 August
Have you been paying attention to The Week's news?
-
The week's best photos
In Pictures A volcano stirs, a deathly flower blooms, and more
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts